Series: The Whole Child · Part 2 of 4
If a child can’t say “my stomach hurts,” they will say it another way. In our records it appears as task refusal, self-injury directed at the abdomen, or an entire afternoon out of range. This post reviews what the research shows about gastrointestinal function in autism, and defines precisely where our role ends and the pediatrician’s begins.
One fact changes the conversation with families more than any other, in our experience: chronic constipation and abdominal pain are not treated with less urgency in autistic children because they are less common, but because they are harder to report. When a child with typical language says their stomach hurts, they go to the pediatrician. When a minimally verbal child expresses it by hitting their abdomen or refusing the work table, too often what they get is a more intensive behavior plan.
That mistake has a technical name in our field. It’s a misidentification of behavioral function. And it has a real cost to the child.
The starting point: the 2010 consensus, still current
In 2010, Pediatrics published a consensus report from a panel of pediatric gastroenterologists, neurologists, immunologists, and developmental specialists led by Timothy Buie [1]. Its core conclusions — written by physicians, not by advocates of alternative therapies — were three: GI disorders are common in autistic individuals; they should be evaluated and treated to the same standard as in any other patient; and in nonverbal or minimally verbal children behavioral problems may be the only outward manifestation of underlying GI distress.
Two years later, Daniel Coury and colleagues published in the same journal a call for a dedicated research agenda on GI conditions in autism, citing the consistency and severity of the problem [2]. And in 2018, Calliope Holingue and colleagues’ systematic review in Autism Research estimated that prevalence of at least one GI symptom in autistic children falls between 23% and 70% depending on study design [3].
That range deserves comment, because it is the kind of figure that gets cited badly. The reason it spans 23% to 70% is not that studies contradict each other: it’s that defining and measuring “GI symptom” in a population with communication difficulties is methodologically hard, and studies using structured parent report find higher figures than those using medical records. The honest statement is that this is a common and probably underdiagnosed problem — not that it affects “7 in 10 autistic children.”
What microbiome studies have found
When the gut microbiomes of autistic children have been systematically compared to neurotypical children, some patterns have recurred. We summarize them with their confidence level, not as established fact.
| Finding | Primary source | How to read it |
|---|---|---|
| Reduced Bifidobacterium; GI symptom severity correlated with autism severity | Adams et al., BMC Gastroenterology 2011 (58 autistic children, 39 controls) [4] | Correlation, not causation. Small sample. Consistent with other work. |
| Elevated Clostridium species | Song, Liu & Finegold, Applied and Environmental Microbiology 2004 [5] | Replicated by several groups. Clinical significance not yet established. |
| Elevated Desulfovibrio; lower microbial diversity | Finegold et al., Anaerobe 2010 [6] | Pyrosequencing study, small sample. |
| Altered bacterial genes for sulfur metabolism and oxidative stress detoxification | Nirmalkar et al., International Journal of Molecular Sciences 2022 [7] | Shotgun metagenomics. Interesting mechanistic finding; not a diagnostic test. |
A caution about this body of literature as a whole. Microbiome research in autism consists largely of cross-sectional studies with small samples and inadequate dietary control — and the diet of a child with severe food selectivity is, by itself, a plausible explanation for an altered microbiome. The direction of causality, for most of these findings, is not established. We do not know whether a different microbiome contributes to symptoms, results from diet and medication use, or both.
Digestive enzyme insufficiency: the most concrete finding
Of everything above, the line of research with the most direct clinical implications is probably the least discussed. It comes from endoscopic biopsy studies, not questionnaires.
In 1999, Karoly Horvath and colleagues evaluated 90 autistic children undergoing endoscopy and found 49% had at least one deficient disaccharidase enzyme (lactase, maltase, sucrase, palatinase, or glucoamylase), and 20% had deficiencies in two or more; lactase deficiency was most common [8]. Brent Williams and colleagues confirmed and extended these findings in PLoS ONE in 2011, also documenting altered intestinal microbiota associated with the carbohydrate digestion impairment [9].
The largest study came from Massachusetts General Hospital and Harvard Medical School: Rafail Kushak, Timothy Buie, and colleagues evaluated intestinal biopsies from 199 autistic individuals aged 22 months to 28 years, finding lactase deficiency in 62%, sucrase deficiency in 16%, and maltase deficiency in 10% [10]. An important detail: the problem was as common in adults as in children, suggesting it isn’t a developmental phase that resolves on its own.
The implication is mechanically simple. If a child cannot digest the lactose in milk or the sucrose in fruit, those undigested sugars reach the intestine where they ferment, producing gas, distension, and pain. And pain, in a child who cannot report it, appears as behavior. This also explains why some families observe notable changes after removing a specific food: not because of any magic property of the food, but because the child couldn’t digest it.
What this means for a family. There is a concrete, established medical test — disaccharidase activity measurement on biopsy during endoscopy — that can identify this. It is not experimental and not from an alternative lab: it is part of the standard gastroenterology workup. The 2010 Buie consensus report specifically recommends endoscopic evaluation in autistic children with persistent GI symptoms [1]. If your child has distension, pain, or recurrent behavioral disturbance tied to meals, it is reasonable to ask your pediatrician whether a referral to pediatric gastroenterology is warranted.
Intestinal permeability: a real finding, an overloaded term
Laura de Magistris and colleagues published a 2010 study in Journal of Pediatric Gastroenterology and Nutrition comparing intestinal permeability across autistic children, their first-degree relatives, and healthy controls. They found elevated permeability in 36.7% of autistic children versus 4.8% of controls [11].
It’s a replicated and methodologically sound finding. At the same time, the popular term “leaky gut” has become a catch-all used to explain almost any symptom and to sell almost any product. Altered intestinal permeability is a measurable phenomenon; “leaky gut” as a universal explanatory diagnosis is not. Both are true and worth holding together.
Probiotics and microbiota transfer: where the evidence actually stands
Probiotics
We’re direct here because that’s what’s warranted. Persico and colleagues’ systematic review of 115 randomized controlled trials specifically examined the probiotic literature and concluded that available RCT evidence is insufficient to support probiotics as a treatment for core autism features [12]. The Gosling 2025 review reaches a compatible conclusion [13]. Trials have been small, using different strains and different protocols, with mixed results.
This is not the same as saying no child benefits. It means that today it cannot be claimed that they work for autism, and that any decision about probiotics for a child belongs to their pediatrician or gastroenterologist, weighing the specific digestive picture rather than the autism diagnosis.
Microbiota transfer therapy
This is the most striking finding in the field and also the most misrepresented.
In 2017, the team of Rosa Krajmalnik-Brown, James Adams, and Dae-Wook Kang at Arizona State University published an open-label, uncontrolled trial of Microbiota Transfer Therapy (MTT) in 18 autistic children with chronic GI symptoms. The protocol combined vancomycin, a bowel cleanse, a stomach acid suppressant, and fecal microbiota transplant from screened healthy donors, followed by maintenance dosing [14]. In 2019 the same team published a two-year follow-up in Scientific Reports on the same 18 children: a 58% reduction in the Gastrointestinal Symptom Rating Scale from baseline, and a 45% reduction in core autism symptoms by professional evaluator [15]. Microbiome changes persisted, with increases in bacterial diversity and in relative abundance of Bifidobacterium and Prevotella.
Editorial accuracy note. We have seen these figures cited as “59%” and “47%.” The figures published by Kang and colleagues in 2019 are 58% (GSRS) and 45% (core symptoms, professional evaluator) [15]. More important than the decimal: this was an open-label study of 18 participants with no placebo group. In a population where assessment depends partly on observation by non-blinded caregivers and evaluators, and across two years of natural development and concurrent therapies, improvement cannot confidently be attributed to the treatment. The authors themselves note the need for placebo-controlled trials. Those phase 2 trials are underway. Until they publish, this is a promising hypothesis, not a treatment. MTT is not clinically available for autism in the United States outside research protocols, and fecal transplant outside authorized trials carries infection risks documented by the FDA.
Early-childhood antibiotics
Several studies have documented higher oral antibiotic use in early childhood among children later diagnosed with autism, compared to controls — including the early medical history analysis by Rebecca Niehus and Catherine Lord [16]. This finding is real and merits investigation, and it is also a textbook example of why correlation isn’t enough: children who receive more antibiotics are children who have more infections and more medical visits, which in turn is associated with more opportunities for early detection. Whether this reflects causation, confounding by indication, or detection bias has been debated for years.
What is an established pediatric recommendation, independent of autism, is antibiotic stewardship: prescribing them when indicated and not for viral infections. That’s decided in the medical visit.
Clinical note for BCBAs and RBTs
Our contribution in this area is measurement, and it’s more valuable than usually recognized.
Indicators warranting communication to the family with a recommendation for medical evaluation: problem behavior with a consistent postprandial pattern; self-injury directed at the abdomen, abdominal pressure against objects, guarding postures; sudden refusal of previously accepted foods; cyclical behavioral disturbance with no identifiable environmental correlate in the functional analysis; regression of mastered skills; problem behavior unresponsive to a well-implemented plan with verified treatment integrity.
Data a pediatric gastroenterologist can use: bowel movement logs (frequency and consistency, Bristol scale if the family can apply it), correlation between problem behavior and time windows relative to meals, latency from intake to episode, and comparison of behavior rates in morning versus afternoon sessions. A one-page graph of that temporal correlation is more useful in the appointment than a narrative description.
Functional analysis integrity. When untreated medical distress operates as a motivating variable, functional analysis results can be unstable or inconsistent across conditions. If you observe that instability, consider a medical cause as an explanatory hypothesis before reformulating the plan a third time.
Role boundary. We do not suggest specific lab tests, do not interpret stool panel results, and do not recommend probiotics, enzymes, or elimination protocols. We describe behavior, provide data, recommend medical consultation, and document the referral in the record. This is what BACB standards 2.01, 2.03, and 3.06 require.
For families
If you suspect something digestive sits behind your child’s behavior, the shortest route doesn’t go through the internet. It goes through two weeks of simple logging — bowel movements, sleep, and what time the hard episodes happened — a copy of the behavioral data your ABA team is already collecting, and a pediatric appointment where you ask specifically whether a referral to pediatric gastroenterology is warranted.
Our team can prepare that data summary for you. You only have to ask.
Questions about your child’s program? Our clinical team can meet with you to review your data, discuss goals, and explain how we coordinate with your pediatrician. Call (813) 655-8159 or write to contact@hopefultherapies.com. We serve families in Brandon, Lakeland and Winter Haven, Florida.
About this series. This post discusses and responds to “The Gut-Brain Connection in Autism: Why Healing the Microbiome Can Transform Neurodevelopmental Health” by Jill Carnahan, MD, published by the Foundation for Alternative and Integrative Medicine. The text on this page is original to Hopeful Therapies. We verified the primary sources the author cites; where our reading of the evidence differs, we say so. The original article includes product recommendations and supplementation protocols that we do not reproduce here, because they fall outside an ABA provider’s scope of practice and because we have no commercial relationship with any manufacturer.
References
- Buie T, Campbell DB, Fuchs GJ III, et al. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics. 2010;125(Suppl 1):S1-S18. doi:10.1542/peds.2009-1878C
- Coury DL, Ashwood P, Fasano A, et al. Gastrointestinal conditions in children with autism spectrum disorder: developing a research agenda. Pediatrics. 2012;130(Suppl 2):S160-S168. doi:10.1542/peds.2012-0900N
- Holingue C, Newill C, Lee LC, Pasricha PJ, Fallin MD. Gastrointestinal symptoms in autism spectrum disorder. Autism Res. 2018;11(1):24-36. doi:10.1002/aur.1854
- Adams JB, Johansen LJ, Powell LD, Quig D, Rubin RA. Gastrointestinal flora and gastrointestinal status in children with autism. BMC Gastroenterol. 2011;11:22. doi:10.1186/1471-230X-11-22
- Song Y, Liu C, Finegold SM. Real-time PCR quantitation of clostridia in feces of autistic children. Appl Environ Microbiol. 2004;70(11):6459-6465. doi:10.1128/AEM.70.11.6459-6465.2004
- Finegold SM, Dowd SE, Gontcharova V, et al. Pyrosequencing study of fecal microflora of autistic and control children. Anaerobe. 2010;16(4):444-453. doi:10.1016/j.anaerobe.2010.06.008
- Nirmalkar K, Qureshi F, Kang DW, Hahn J, Adams JB, Krajmalnik-Brown R. Shotgun metagenomics study suggests alteration in sulfur metabolism and oxidative stress in children with autism. Int J Mol Sci. 2022;23(21):13481. doi:10.3390/ijms232113481
- Horvath K, Papadimitriou JC, Rabsztyn A, Drachenberg C, Tildon JT. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr. 1999;135(5):559-563. doi:10.1016/s0022-3476(99)70052-1
- Williams BL, Hornig M, Buie T, et al. Impaired carbohydrate digestion and transport and mucosal dysbiosis in the intestines of children with autism. PLoS One. 2011;6(9):e24585. doi:10.1371/journal.pone.0024585
- Kushak RI, Lauwers GY, Winter HS, Buie TM. Intestinal disaccharidase activity in patients with autism. Autism. 2011;15(3):285-294. doi:10.1177/1362361310369142
- de Magistris L, Familiari V, Pascotto A, et al. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr. 2010;51(4):418-424. doi:10.1097/MPG.0b013e3181dcc4a5
- Persico AM, Asta L, Chehbani F, et al. The pediatric psychopharmacology of autism spectrum disorder — Part II: The future. Prog Neuropsychopharmacol Biol Psychiatry. 2025;136:111176. sciencedirect.com
- Gosling CJ, Boisseleau L, Solmi M, et al. Complementary, alternative and integrative medicine for autism: an umbrella review and online platform. Nat Hum Behav. 2025;9(12):2610-2619. nature.com/articles/s41562-025-02256-9
- Kang DW, Adams JB, Gregory AC, et al. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. 2017;5(1):10. doi:10.1186/s40168-016-0225-7
- Kang DW, Adams JB, Coleman DM, et al. Long-term benefit of Microbiota Transfer Therapy on autism symptoms and gut microbiota. Sci Rep. 2019;9(1):5821. nature.com/articles/s41598-019-42183-0
- Niehus R, Lord C. Early medical history of children with autism spectrum disorders. J Dev Behav Pediatr. 2006;27(2 Suppl):S120-S127. doi:10.1097/00004703-200604002-00010
Important notice. Hopeful Therapies provides applied behavior analysis (ABA) services. We are not a medical provider and do not diagnose or treat medical conditions, nor do we prescribe diets, supplements, enzymes, probiotics, or medications. This content is educational and does not constitute medical advice or substitute for the relationship with your pediatrician or other qualified health professional. Do not start, stop, or change any treatment, diet, or supplement based on this post. Fecal microbiota transplant outside authorized research protocols carries documented risks and should not be attempted independently. Our services are delivered in accordance with the BACB Ethics Code for Behavior Analysts and applicable Florida Agency for Health Care Administration (AHCA) requirements. We have no commercial relationship with any supplement manufacturer, laboratory, or testing provider mentioned or linked in this series.
